

**UNITED STATES DISTRICT COURT FOR THE  
DISTRICT OF MASSACHUSETTS**

---

DONALD C. HUTCHINS,  
Plaintiff,

Civil Action No. 04-30126-MAP

v.

CARDIAC SCIENCE, INC.,  
Defendant.

---

**DEFENDANT’S MEMORANDUM OF LAW IN OPPOSITION TO PLAINTIFF’S  
SECOND MOTION FOR A TEMPORARY RESTRAINING ORDER**

**INTRODUCTION**

Plaintiff’s August 23 motion for a temporary restraining order (Court Docket #12) should be denied for the same reasons previously stated in Defendant’s previous opposition motion (Court Docket #8). First, Plaintiff is not likely to prevail on the merits in this case, as evidenced by Cardiac Science Inc.’s (“Cardiac Science”) pending Rule 12(b) motion to dismiss (Court Docket #9). Second, Plaintiff’s claim of irreparable harm is based upon an incorrect understanding of the so called “lock up” agreement and because this court does not have jurisdiction to impact the lock-up agreement between Cardiac Science and Compliant Corporation.

**ARGUMENT**

Plaintiff has failed to establish the requirements for a grant of a temporary restraining order. Plaintiff does not have a likelihood of success on the merits and Plaintiff will suffer no irreparable harm. In light of Plaintiff’s small chances of winning the case and lack of harm from not granting the motion, the motion should be denied.

**I. PLAINTIFF IS UNLIKELY TO PREVAIL ON THE MERITS OF THE CASE**

As more fully argued in Cardiac Science's Amended Memorandum of Law in Support of its Motion to Dismiss Under Fed. R. Civ. P. 12(b)(1) and 12(b)(6) (Court Docket #11), Plaintiff has not stated any claims upon which relief can be granted and this Court does not even have jurisdiction to hear several of his claims. Counts I, II, and III of Plaintiff's Complaint should be dismissed because Plaintiff did not meet the conditions precedent in the June 1, 1994 licensing agreement to reclaim his intellectual property. Therefore, Cardiac Science is the exclusive licensee of the intellectual property at issue and cannot be an infringer. The negligence counts in the Complaint, Counts IV and V, should be dismissed because Plaintiff has not demonstrated that Cardiac Science owed him a duty and or that Cardiac Science is the proximate cause of his alleged damages. The breach of contract claim, Count VI, should be dismissed because Plaintiff failed to provide the notice of breach required by the June 1, 1994 agreement. Counts I, II, III, and VI should also be dismissed because this Court lacks jurisdiction to adjudicate whether there has been a breach of the June 1, 1994 license agreement according to the terms of the agreement. As Cardiac Science's motion demonstrates, all of Plaintiff's claims should be dismissed and therefore he is not likely to succeed on the merits of the case.

**II. PLAINTIFF WILL NOT BE HARMED IF THE TEMPORARY RESTRAINING ORDER IS DENIED**

Plaintiff misinterprets the nature of the lock-up agreement between Cardiac Science and Compliant Corporation and the requested temporary restraining order would not prevent any perceived harm. Plaintiff's requested order would restrain Cardiac Science from disbursing any lock-up installments. However, Cardiac Science has long since transferred the required shares under the lock-up agreement to Compliant. There is no ongoing transfer of "lock-up" shares from Cardiac Science to Compliant pursuant to the lock up agreement and thus nothing to enjoin.

The shares were transferred at the outset, and the lock-up agreement merely prevents Compliant from selling all of its acquired shares at once. (Exhibit 1, p.1 ¶ 4). Compliant can only sell its shares according to a prescribed schedule in the lock-up agreement. (Exhibit 1, p. 10). Any order to prevent the transfer of shares pursuant to the lock-up agreement would therefore have to be issued against Compliant, a non-party to this action. Such an order against Cardiac Science would accomplish nothing and prevent no harm to Plaintiff, so the motion for a temporary restraining order should be denied.

### CONCLUSION

Plaintiff has failed to establish: (1) a likelihood of success on the merits and (2) that he will be irreparably harmed by a failure to grant a temporary restraining order. Therefore, his motion should be denied.

Respectfully submitted,

**CARDIAC SCIENCE, INC.**

Dated: August 24, 2004

Randall T. Skaar  
Scott G. Ulbrich  
**PATTERSON, THUENTE, SKAAR  
& CHRISTENSEN, P.A.**  
4800 IDS Center  
80 South 8<sup>th</sup> Street  
Minneapolis, MN 55402-2100  
Tel: (612) 349-5740  
Fax: (612) 349-9266

By: /s/ Paul H. Rothschild  
Paul H. Rothschild  
**BACON & WILSON P.C.**  
33 State Street  
Springfield, MA 01103  
Phone: (413) 781-0560  
Fax: (413) 739-7740  
BBO# 431100

### CERTIFICATE OF SERVICE

I, PAUL H. ROTHSCILD, hereby certify that on the 24<sup>th</sup> day of August 2004, I caused a copy of the foregoing Defendant's Memorandum of Law in Opposition to Plaintiff's Second Motion for a Temporary Restraining Order to be served upon all interested parties by mailing a copy thereof, postage prepaid, first class mail to:

Donald C. Hutchins  
1047 Longmeadow Street  
Longmeadow, MA 01106.

/s/ Paul H. Rothschild  
PAUL H. ROTHSCILD

## CARDIAC SCIENCE, INC.

## REGISTRATION RIGHTS AND LOCK-UP AGREEMENT

This Registration Rights and Lock-Up Agreement (this "Agreement") is entered into as of October 21, 2003 (the "Effective Date"), by and among Cardiac Science, Inc., a Delaware corporation (the "Company"), and Compliant Corporation, a Delaware corporation ("Compliant").

WHEREAS, the Board of Directors of the Company and Compliant deem it in the best interests of their respective companies and their respective shareholders to enter into that certain Asset Purchase Agreement dated as of the Effective Date (the "Asset Purchase Agreement"), pursuant to which Cardiac will acquire a significant portion of Compliant's assets (the "Asset Purchase") and, in furtherance thereof, have approved the Asset Purchase and the transactions set forth in the Asset Purchase Agreement. Pursuant to the Asset Purchase Agreement, the Company will issue to Compliant 10,250,000 shares of its Common Stock, \$0.001 par value per share ("Common Stock") as consideration for the Asset Purchase (the "Total Shares");

WHEREAS, in connection with Asset Purchase Agreement, the Company has agreed to register for offer and sale by Compliant, the Total Shares;

WHEREAS, pursuant to the terms of the Asset Purchase Agreement, 8,200,00 of the Total Shares are deliverable directly to Compliant on the Effective Date (the "Closing Shares"), and Compliant has agreed to a "lock-up" of 7,125,000 of the Closing Shares (the "Restricted Shares") on the terms and conditions more fully set forth herein;

WHEREAS, pursuant to the terms of the Asset Purchase Agreement, the parties are entering into a General Escrow Agreement, dated of even date herewith, pursuant to which 1,025,000 of the Total Shares (the "General Escrow Shares") shall be placed in escrow, all of which General Escrow Shares shall have certain "lock-up" restrictions applicable thereto on the terms and conditions more fully set forth herein;


WHEREAS, pursuant to the terms of the Asset Purchase Agreement, the parties are entering into an Oxygen Escrow Agreement, dated of even date herewith, pursuant to which 1,025,000 of the Total Shares (the "Oxygen Escrow Shares") shall be placed in escrow, 775,000 of which Oxygen Escrow Shares shall have certain "lock-up" restrictions applicable thereto on the terms and conditions more fully set forth herein; and

WHEREAS, the parties hereto desire to enter into this Agreement to evidence the foregoing agreement of the Company and the mutual covenants of the parties relating thereto.

NOW THEREFORE, in consideration of the mutual agreements, covenants and conditions contained herein, the Company and Compliant hereby agree as follows:

1. **Definitions.** As used herein:

1.1 The terms "register," "registered," and "registration" refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act (as defined below), and the applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.



1.2 The term "Registrable Shares" means and includes (i) all 10,250,000 of the shares of Common Stock originally issued to Compliant pursuant to the Asset Purchase Agreement, and (ii) any Common Stock of the Company issued, or issuable upon the conversion or exercise of any warrant, right or other security which is issued, as a result of a stock split, dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in (i) above.

1.3 The term "Securities Act" means the Securities Act of 1933, as amended.

1.4 The term "Escrow Shares" means collectively the General Escrow Shares and the Oxygen Escrow Shares.

## 2. Registration Rights.

2.1 "S-3" Registration. The Company shall prepare and file with the Securities and Exchange Commission (the "SEC"), within thirty (30) days after the Effective Date (or, if the delivery of the audit report referenced in Section 9.9 of the Asset Purchase Agreement does not occur by November 12, 2003, then within that number of days after the Effective Date that equals 30 plus the number of days of such delay beyond November 12, 2003), a registration statement on the Form S-3 (the "S-3") for the purpose of effecting a registration of the offer and resale of all Registrable Shares by Compliant, and shall use all reasonable efforts to effect, as soon as practicable after the date hereof, such registration (including, without limitation, the execution of an undertaking to file post-effective amendments and appropriate qualification under applicable state securities laws and appropriate compliance with exemptive regulations issued under the Securities Act and any other governmental requirements and regulations) as would permit or facilitate the sale and distribution of the Registrable Shares.

### 2.2 Effectiveness; Procedures.

(a) The Company will use all reasonable efforts to maintain the effectiveness of any registration statement pursuant to which any of the Registrable Shares are being offered for up to two years from the closing date of the Asset Purchase Agreement (the "Effective Time"); provided, however, that such two year period shall be extended for a period of time equal to any period of time during which the Registration Statement may not be used by Compliant because it does not contain sufficient current public information about the Company.

(b) The Company will from time to time amend or supplement such registration statement and the prospectus contained therein as and to the extent necessary to comply with the Securities Act and any applicable state securities statute or regulation.

(c) The Company will keep Compliant advised as to the initiation of proceedings for such registration and as to the completion thereof, and will advise Compliant, upon request, of the progress of such proceedings. In addition, the Company will accord to Compliant all rights (including the right to perform appropriate "due diligence") customarily accorded to selling stockholders in secondary distributions. At the expense of the Company, the Company will take all necessary actions to properly register the Registrable Shares for trading in the public markets by complying with all applicable laws, regulations, rules and customs, including (i) keeping such registration current and effective by such action as may be necessary or appropriate, including the filing of post-effective amendments and supplements to any Registration Statement or Prospectus, for such period (not to exceed two years) as is necessary to permit the sale and distribution of the



Registrable Shares pursuant thereto, (ii) taking all necessary action under any applicable blue sky or other state securities law to permit such sale and/or distribution, all as requested by Compliant, provided that the Company shall not be required to so register or qualify the Registrable Shares in any jurisdiction if, solely as a result thereof, the Company must qualify generally to do business therein or consent to general service of process therein, (iii) complying with applicable requirements of all regulatory entities, including The National Association of Securities Dealers, Inc., (iv) furnishing Compliant such number of registration statements, prospectuses, supplements, amendments, offering circulars and other documents incidental thereto as Compliant from time to time may reasonably request, (v) listing all Registrable Shares included therein on each securities exchange on which securities of the same class are then listed, and (vi) taking any other action as shall be necessary to properly effectuate registration of the Shares in compliance with all laws, regulations and other such requirements.

### 2.3 Registration Indemnification.

(a) Indemnification of Compliant. In the event that the Company registers any of the Registrable Shares under the Securities Act, the Company will indemnify and hold harmless Compliant and its directors and officers and each person, if any, who controls Compliant from and against any and all losses, claims, damages, expenses or liabilities (or any action in respect thereof), to which it becomes subject under the Securities Act or under any other statute or at common law or otherwise, and, except as hereinafter provided, will reimburse Compliant and each such controlling person for any legal or other expenses reasonably incurred by them or any of them, as such expenses are incurred, in connection with investigating or defending any actions whether or not resulting in any liability, insofar as such losses, claims, damages, expenses, liabilities or actions arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the registration statement, in any preliminary or amended preliminary prospectus or in the prospectus (or the registration statement or prospectus as from time to time amended or supplemented by the Company); (ii) arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein not misleading; or (iii) any violation by the Company of the Securities Act, the Securities Exchange Act of 1934, as amended (the "Exchange Act"), a state securities law or any rule or regulation under the Securities Act, the Exchange Act or any state securities law; provided, however, that the indemnity contained in this Section 2.3(a) will not apply where such untrue statement or omission was made in such registration statement, preliminary or amended, preliminary prospectus or prospectus in reliance upon and in conformity with information furnished in writing to the Company in connection therewith by Compliant or any such controlling person expressly for use therein.

(b) Indemnification of Company. In the event that the Company registers the offer and resale of any of the Registrable Shares under the Securities Act, Compliant will indemnify and hold harmless the Company, each of its directors, each of its officers who have signed the registration statement, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act from and against any and all losses, claims, damages, expenses or liabilities (or any action in respect thereof), to which it becomes subject under the Securities Act or under any other statute or at common law or otherwise, and, except as hereinafter provided, will reimburse the Company and each such director, officer or controlling person for any legal or other expenses reasonably incurred by them or any of them, as such expenses are incurred, in connection with investigating or defending any actions whether or not resulting in any liability, insofar as such losses, claims, damages, expenses, liabilities or actions arise out of or are based upon any untrue

statement or alleged untrue statement of a material fact contained in the registration statement, in any preliminary or amended preliminary prospectus or in the prospectus (or the registration statement or prospectus as from time to time amended or supplemented) or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein not misleading, but only insofar as any such statement or omission was made in reliance upon and in conformity with information furnished in writing to the Company in connection therewith by Compliant, expressly for use therein. Indemnification by the Company hereunder will be made solely against the General Escrow Fund as an indemnification claim pursuant to Section 11.2(a) of the Asset Purchase Agreement.

**2.4 Contribution.** If the indemnification provided for in Section 2.3 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties' relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission.

**2.5 Expenses.** In the case of a registration under Sections 2.1, the Company shall bear all costs and expenses of each such registration, including, but not limited to, printing, legal and accounting expenses, SEC filing fees and "blue sky" fees and expenses; provided, however, that the Company shall have no obligation to pay or otherwise bear (i) any portion of any underwriter's commissions or discounts attributable to the Registrable Shares being offered and sold by Compliant, or (ii) any of such expenses if the payment of such expenses by the Company is prohibited by the laws of a state in which such offering is qualified and only to the extent so prohibited.

**2.6 Termination of Registration Rights.** The obligations of the Company to register any Registrable Shares pursuant to this Section 2 shall terminate upon the earlier of the following: (i) two (2) years from the Effective Time (as defined in Section 2.2 hereof); or (ii) if all of the Registrable Shares may immediately be sold under Rule 144 during any ninety (90) day period.

**3. Representations and Warranties of Compliant.** This Agreement and the Asset Purchase Agreement is made with Compliant in reliance upon Compliant's representations to the Company, which by Compliant's execution of this Agreement it hereby confirms, that:

**3.1 No Restrictions.** There are no limitations or restrictions on Compliant's power to invest in the Company and to perform its obligations under this Agreement.

**3.2 Purchase Entirely for Own Account.** The Registrable Shares will be acquired for investment for Compliant's own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and Compliant has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, Compliant further represents that Compliant does not have any contract, undertaking, agreement or

arrangement with any person to sell, short sell, transfer or grant participations, to such person or to any third person, with respect to any of the Registrable Shares.

**3.3 Disclosure of Information.** Compliant believes it has received all the information it considers necessary or appropriate for deciding whether to acquire the Registrable Shares. Compliant further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Registrable Shares.

**3.4 Investment Experience.** Compliant can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Registrable Shares. Compliant also represents it has not been organized for the purpose of acquiring the Registrable Shares.

**3.5 Accredited Shareholder.** Compliant is an "accredited investor" within the meaning of Rule 501 of Regulation D under the Securities Act as presently in effect.

**3.6 Restricted Securities.** Compliant understands that the Registrable Shares are characterized as "restricted securities" under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances. In this connection, Compliant represents that it is familiar with Rule 144 under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

**3.7 Limitations on Transfer.** Without limiting in any way the representations set forth above, Compliant further agrees not to make any disposition or assignment of all or any portion of the Registrable Shares unless:

(a) there is then in effect a registration statement filed under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or

(b) Compliant shall have notified the Company of the proposed disposition and shall have furnished the Company with a reasonably detailed statement of the circumstances surrounding the proposed disposition and shall furnish customary transferor representations as may reasonably be requested by the Company, and (ii) if reasonably requested by the Company, Compliant shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act.

**3.8 Lock-up/Further Restrictions on Transfer.**

(a) Compliant hereby agrees that it shall not sell, transfer, assign, convey, donate, pledge, encumber, alienate or in any way dispose of (any one of the foregoing, a "Transfer") Restricted Shares on or before the earlier of (i) two business days after the date the S-3 is deemed effective or declared effective by the SEC (the "S-3 Effective Date") or (ii) the first anniversary of the S-3 Effective Date, unless Compliant otherwise establishes to the reasonable satisfaction of the



Company (including, if necessary, presentation of an opinion of counsel, reasonably satisfactory to the Company) that an exemption from registration under the Securities Act with respect to such proposed transfer is available; provided, however, that Compliant shall be permitted to pledge any or all of the Restricted Shares to secure the obligations of Compliant under any bridge financing arrangements entered into by Compliant with its stockholders or their Affiliates in connection with the closing of the Asset Purchase Agreement, and any such pledgee shall hold such shares subject to all of the terms, conditions and restrictions contained in this Agreement, including without limitation this Section 3.8(a) and the "lock-up" provisions of section 3.8(b).

(b) Subsequent to the earlier of (i) two business days after the S-3 Effective Date or (ii) the first anniversary of the Closing Date, the Restricted Shares shall be released from the "lock-up" on Transfers set forth in Section 3.8(a) pursuant to the timetable set forth in Schedule 1 hereto.

(c) Compliant hereby agrees that, except as set forth in Section 3(g)(i) of the Oxygen Escrow Agreement with respect to 250,000 of the Escrow Shares thereunder (the "Unrestricted Escrow Shares"), it shall not Transfer the Escrow Shares on or before the date (the "Escrow Shares Release Date") that is the later of (i) the date that is sixty (60) days after the Effective Date, or (ii) the S-3 Effective Date, but not later than the first anniversary of the Closing Date.

(d) Subsequent to the Escrow Shares Release Date, the Escrow Shares shall be released from a "lock-up" on Transfers only pursuant to the timetable set forth in Schedule 2 hereto (except for the Unrestricted Escrow Shares, which shall not be subject to such "lock-up").

(e) Any purported or attempted Transfer whether voluntary or involuntary, in violation of Section 3.8 shall be null and void and of no legal effect.

**3.9 Stop Transfer Instructions; No Requirement to Transfer.** Compliant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate "stop transfer" instructions to its transfer agent. The Company shall not be required (i) to transfer or have transferred on its books any shares of Common Stock that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or the Asset Purchase Agreement or (ii) to treat as owner of such shares of Common Stock or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such shares of Common Stock shall have been so transferred in violation of any provision of this Agreement or the Asset Purchase Agreement.

**3.10 Legends.** Compliant understands and agrees that there will be placed on the certificates evidencing the ownership of the Registrable Shares the following legends, in addition to any legends required by applicable securities laws, by the Company's certificate of incorporation, as amended from time to time, until such time as such legends or portions thereof are no longer required in contemplation of the provisions of this Agreement, the Asset Purchase Agreement or the Securities Act:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE OFFERED, SOLD, PLEDGED, EXCHANGED, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT IN ACCORDANCE WITH THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THE SECURITIES MAY NOT BE OFFERED, SOLD,

PLEDGED, EXCHANGED OR TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT (AND CURRENT PROSPECTUS) IS IN EFFECT AS TO THE OFFER AND SALE OF THE SECURITIES, OR (2) AN EXEMPTION FROM REGISTRATION IS AVAILABLE, OR (3) THE SECURITIES ARE SOLD PURSUANT TO RULE 144 OF THE SECURITIES ACT. the ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE OR OTHER NATIONAL SECURITIES LAWS. FURTHERMORE, THE HOLDER OF THESE SECURITIES HAS AGREED PURSUANT TO THE TERMS OF A REGISTRATION RIGHTS AND LOCK-UP AGREEMENT (A COPY OF WHICH IS AVAILABLE UPON REQUEST OF THE COMPANY) NOT TO TRANSFER THE SAME UNTIL A CERTAIN DATE.

Any legend required by the laws of the State of California including any legend required by the California Department of Corporations and Sections 417 and 418 of the Code.

4. **Assignability.** This Agreement shall be binding upon and inure to the benefit of the permitted heirs, successors and assigns of the parties hereto, but any purported assignment or transfer is subject to the terms of this Agreement, including but not limited to, Section 2.6 and Section 3.8.

5. **Governing Law; Venue.** This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to Delaware's conflict of law principles, and shall be binding on the successors and assigns of the parties hereto. The venue for any action, suit or proceeding relating to or arising from this Agreement shall be only a state or federal court of competent jurisdiction located in the State of Delaware, and all objections to venue and personal jurisdiction in any action or proceeding so commenced are hereby irrevocably waived.

6. **Entire Agreement.** This Agreement, the Escrow Agreements and the Asset Purchase Agreement constitute the full and entire understanding and agreement among the parties with regard to the subject matter hereof.

7. **Amendment.** Any modification, amendment, or waiver of this Agreement or any provision hereof, including this sentence, either retroactively or prospectively, shall be in writing and executed by the Company and Compliant which shall be binding upon the parties hereto.

8. **Counterparts.** This Agreement may be executed in any number of counterparts, each of which will be an original as regards any party whose signature appears thereon and all of which together will constitute one and the same instrument. This Agreement will become binding when one or more counterparts hereof, individually or taken, will bear the signatures of both parties reflected hereon as signatories.

9. **Notice.** Any notices and other communications required or permitted under this Agreement shall be effective if in writing and delivered personally or sent by telecopier, federal express or registered or certified mail, postage prepaid, addressed as follows:

If to Compliant:

Compliant Corporation  
c/o 4670 Richmond Road  
Suite 300  
Warrensville Heights, Ohio 44128  
Telecopier : (440) 519-3764  
Attn: Steven W. Lindseth

with a copy to:

Calfee, Halter, Griswold LLP  
1400 MacDonald Investment Center  
800 Superior Avenue  
Cleveland, OH 44114-2688  
Telecopier: (216) 251-0816  
Attn: Gerald A. Monroe, Esq.

If to the Company:

Cardiac Science, Inc.  
1900 Main Street, Suite 700  
Irvine, CA 92614  
Telecopier: (949) 951-7315  
Attention: Chief Executive Officer

with a copy to:

Stradling Yocca Carlson & Rauth  
660 Newport Center Drive, Suite 1600  
Newport Beach, CA 92660  
Telecopier: (949) 725-4100  
Attention: Shivbir S. Grewal, Esq.

Unless otherwise specified herein, such notices or other communications shall be deemed effective (a) on the date delivered, if delivered personally, (b) two business days after being sent, if sent by Federal Express, (c) one business day after being sent, if sent by telecopier with confirmation of good transmission and receipt, and (d) four business days after being sent, if sent by registered or certified mail. Each of the parties herewith shall be entitled to specify another address by giving notice as aforesaid to each of the other parties hereto.

10. **Stamp Duty.** Any stamp duty, transfer tax or similar tax payable in connection with the transfer by Compliant of its Registrable Shares shall be payable by Compliant.

[SIGNATURES ON NEXT PAGE]


IN WITNESS WHEREOF, the parties hereto have caused this Registration Rights and Lock-up Agreement to be executed as of the Effective Date.

**Cardiac Science, Inc.,**  
a Delaware corporation



By: Raymond Cohen  
Its: Chief Executive Officer

**Compliant Corporation,**  
a Delaware corporation



By: ROBERT I. THOMPSON  
Its: PRESIDENT & CEO



**SCHEDULE 1****Restricted Shares Release**

Number of Days after the earlier of (i) the S-3 Effective Date or (ii) the first anniversary of the Closing Date after which the Restricted Shares are Transferable	Maximum Percentage of Released Restricted Shares (cumulative)
0 days	8 1/3%
after 30 days	16 2/3%
after 60 days	25.00%
after 90 days	33 1/3%
after 120 days	41 2/3%
after 150 days	50.00%
after 180 days	58 1/3%
after 210 days	66 2/3%
after 240 days	75.00%
after 270 days	83 1/3%
after 300 days	91 2/3%
after 330 days	100.00%

**SCHEDULE 2****Escrow Shares Release**

Number of Days after the Escrow Shares Release Date after which the Escrow Shares are Transferable	Maximum Percentage of Released Escrow Shares (cumulative)
0 days	8 1/3%
after 30 days	16 2/3%
after 60 days	25.00%
after 90 days	33 1/3%
after 120 days	41 2/3%
after 150 days	50.00%
after 180 days	58 1/3%
after 210 days	66 2/3%
after 240 days	75.00%
after 270 days	83 1/3%
after 300 days	91 2/3%
after 330 days	100.00%

6

7